Prostate Cancer-Specific Positron Emission Tomography with Different Radiotracers. | ||
| Egyptian Journal Nuclear Medicine | ||
| Article 3, Volume 21, Issue 2, December 2020, Pages 17-33 PDF (542.35 K) | ||
| Document Type: Review Article | ||
| DOI: 10.21608/egyjnm.2020.140410 | ||
| Author | ||
| Alshemeili, M. | ||
| Nuclear Medicine Department, Faculty of Medicine, Claude Bernard University Lyon, France. | ||
| Abstract | ||
| Imaging evaluation of prostate cancer needs to be tailored for various radiopharmaceuticals being remarkably heterogeneous disease. Positron emission tomography (PET) has played a relatively limited role in prostate cancer imaging. However, in recent years, several new PET tracers have emerged, offering potential improvements in diagnostic performance for both the detection of prostate cancer metastases at initial staging and the localization of recurrent disease. We reviewed the literature for prostate cancer PET tracers that are either being used for patient management or being evaluated in clinical research trials. For each tracer, we compiled clinically relevant background information and evidence supporting clinical use, with the intention of providing a high-yield primer for urologists managing patients with prostate cancer.18F-FDG, 18F-NaF, ¹¹C-choline, and 18F-fluciclovine have all proven useful for prostate cancer imaging, though the utility of each of these tracers is limited to targeted management questions and particular clinical settings. In contrast, the newer prostate-specific membrane antigen (PSMA) agents may prove useful as general purpose PET tracers for prostate cancer imaging. Numerous other novel PET tracers have shown promising results in pre-clinical studies. OBJECTIVE: Recent advances of current state of PET radiotracers for potential use in the imaging evaluation of prostate cancer. | ||
| Keywords | ||
| Prostate cancer; radiotracers; positron emission tomography | ||
|
Statistics Article View: 197 PDF Download: 273 |
||
